Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 3, 2015, Pages 755-760

  Capper, Michael J ^a   O'Neill, Paul M ^a   Fisher, Nicholas ^b,c   Strange, Richard W ^a   Moss, Darren ^b   Ward, Stephen A ^b   Berry, Neil G ^a   Lawrenson, Alexandr S ^a   Hasnain, S Samar ^a   Biagini, Giancarlo A ^b   Antonyuk, Svetlan V ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Cytochrome bc1< inf>; Drug discovery; Malaria; Membrane protein; Plasmodium falciparum

Indexed keywords

4(1H) PYRIDONE DERIVATIVE; ANTIMALARIAL AGENT; CYTOCHROME; CYTOCHROME BC 1; GSK 932121; GW 844520; UNCLASSIFIED DRUG; PYRIDONE DERIVATIVE; UBIQUINOL CYTOCHROME C REDUCTASE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BOVINAE; COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; MALARIA CONTROL; MALARIA FALCIPARUM; MITOCHONDRIAL TOXICITY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; Q1 BINDING SITE; CHEMISTRY; METABOLISM;

PLASMODIUM FALCIPARUM;

ANTIMALARIALS; BINDING SITES; ELECTRON TRANSPORT COMPLEX III; MOLECULAR DOCKING SIMULATION; PYRIDONES;

EID: 84922439701     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416611112     Document Type: Article

References (62)

1. WHO (2012) WHOjWorld Malaria Report 2012 (World Health Organization, Geneva).
2. Murray CJL, et al. (2012) Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379(9814):413-431.
3. Mendis K, et al. (2009) From malaria control to eradication: The WHO perspective. Trop Med Int Health 14(7):802-809.
4. Greenwood BM, et al. (2008) Malaria: Progress, perils, and prospects for eradication. J Clin Invest 118(4):1266-1276.
5. Kessl JJ, Meshnick SR, Trumpower BL (2007) Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol 23(10):494-501.
6. Breman JG (2001) The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64(1-2, Suppl):1-11.
7. Färnert A, et al. (2003) Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: Case reports. BMJ 326(7390):628-629.
8. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DBA; Malarone Clinical Trials Study Group (1999) Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria. Am J Trop Med Hyg 60(4):533-541.
9. Kremsner PG, Krishna S (2004) Antimalarial combinations. Lancet 364(9430):285-294.
10. Mutabingwa TK, et al. (2005) Amodiaquine alone, amodiaquine+ sulfadoxinepyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: A four-arm randomised effectiveness trial. Lancet 365(9469):1474-1480.
11. Fleck SL, Pudney M, Sinden RE (1996) The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Trans R Soc Trop Med Hyg 90(3):309-312.
12. Berry EA, Guergova-Kuras M, Huang L-S, Crofts AR (2000) Structure and function of cytochrome bc complexes. Annu Rev Biochem 69:1005-1075.
13. Rieske JS, Hansen RE, Zaugg WS (1964) Studies on the Electron Transfer System. J Biol Chem 239:3017-3022.
14. Iwata S, et al. (1998) Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science 281(5373):64-71.
15. Mitchell P (1976) Possible molecular mechanisms of the protonmotive function of cytochrome systems. J Theor Biol 62(2):327-367.
16. Crofts AR, et al. (1999) Mechanism of ubiquinol oxidation by the bc(1) complex: Role of the iron sulfur protein and its mobility. Biochemistry 38(48):15791-15806.
17. Berry EA, Huang L-S (2011) Conformationally linked interaction in the cytochrome bc (1) complex between inhibitors of the Q(o) site and the Rieske iron-sulfur protein. Biochim Biophys Acta 1807(10):1349-1363.
18. Srivastava IK, Vaidya AB (1999) A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43(6):1334-1339.
19. Painter HJ, Morrisey JM, Mather MW, Vaidya AB (2007) Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446(7131):88-91.
20. Birth D, Kao W-C, Hunte C (2014) Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat Commun 5:4029.
21. Fry M, Pudney M (1992) Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43(7):1545-1553.
22. Nixon GL, et al. (2013) Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother 68(5):977-985.
23. Barton V, Fisher N, Biagini GA, Ward SA, O'Neill PM (2010) Inhibiting Plasmodium cytochrome bc1: A complex issue. Curr Opin Chem Biol 14(4):440-446.
24. Korsinczky M, et al. (2000) Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44(8):2100-2108.
25. Fisher N, et al. (2012) Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J Biol Chem 287(13):9731-9741.
26. Kessl JJ, Ha KH, Merritt AK, Meshnick SR, Trumpower BL (2006) Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae. Mol Biochem Parasitol 146(2):255-258.
27. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB (1999) Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 33(4):704-711.
28. Fisher N, Meunier B (2008) Molecular basis of resistance to cytochrome bc1 inhibitors. FEMS Yeast Res 8(2):183-192.
29. Biagini GA, et al. (2008) Acridinediones: Selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol 73(5):1347-1355.
30. Nilsen A, et al. (2013) Quinolone-3-diarylethers: A new class of antimalarial drug. Sci Transl Med 5:177ra37.
31. Pidathala C, et al. (2012) Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). J Med Chem 55(5):1831-1843.
32. Edwards G, Biagini GA (2006) Resisting resistance: Dealing with the irrepressible problem of malaria. Br J Clin Pharmacol 61(6):690-693.
33. Bueno JM, et al. (2011) Potent antimalarial 4-pyridones with improved physicochemical properties. Bioorg Med Chem Lett 21(18):5214-5218.
34. Yeates CL, et al. (2008) Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J Med Chem 51(9):2845-2852.
35. Xiang H, et al. (2006) Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. J Pharm Sci 95(12):2657-2672.
36. Jiménez-Díaz MB, et al. (2009) Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother 53(10):4533-4536.
37. Bueno JM, et al. (2012) Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1. Future Med Chem 4(18): 2311-2323.
38. Gao X, et al. (2003) Structural basis for the quinone reduction in the bc1 complex: A comparative analysis of crystal structures of mitochondrial cytochrome bc1 with bound substrate and inhibitors at the Qi site. Biochemistry 42(30):9067-9080.
39. Li H, Zhu X-L, Yang W-C, Yang G-F (2014) Comparative kinetics of Qi site inhibitors of cytochrome bc1 complex: Picomolar antimycin and micromolar cyazofamid. Chem Biol Drug Des 83(1):71-80.
40. Berry EA, et al. (2010) Ascochlorin is a novel, specific inhibitor of the mitochondrial cytochrome bc1 complex. Biochim Biophys Acta 1797(3):360-370.
41. Vallières C, et al. (2012) HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex. Antimicrob Agents Chemother 56(7):3739-3747.
42. Huang LS, Cobessi D, Tung EY, Berry EA (2005) Binding of the respiratory chain inhibitor antimycin to the mitochondrial bc1 complex: A new crystal structure reveals an altered intramolecular hydrogen-bonding pattern. J Mol Biol 351(3):573-597.
43. Hunte C, Koepke J, Lange C, Rossmanith T, Michel H (2000) Structure at 2.3 A resolution of the cytochrome bc(1) complex from the yeast Saccharomyces cerevisiae cocrystallized with an antibody Fv fragment. Structure 8(6):669-684.
44. Esser L, et al. (2004) Crystallographic studies of quinol oxidation site inhibitors: A modified classification of inhibitors for the cytochrome bc(1) complex. J Mol Biol 341(1):281-302.
45. Xia D, et al. (1997) Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science 277:60-66.
46. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (2007) Circumventing the Crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97(2):539-547.
47. Biagini GA, et al. (2012) Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proc Natl Acad Sci USA 109(21):8298-8303.
48. Doggett JS, et al. (2012) Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci USA 109(39):15936-15941.
49. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Macromol Crystallogr PT A 276:307-326.
50. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66(Pt 1):22-25.
51. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3): 240-255.
52. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
53. Lebedev AA, et al. (2012) JLigand: A graphical tool for the CCP4 template-restraint library. Acta Crystallogr D Biol Crystallogr 68(Pt 4):431-440.
54. Laskowski RA, Swindells MB (2011) LigPlot+ : Multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51(10):2778-2786.
55. Sievers F, et al. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539.
56. Warman AJ, et al. (2013) Antitubercular pharmacodynamics of phenothiazines. J Antimicrob Chemother 68(4):869-880.
57. Nilsen A, et al. (2014) Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers. J Med Chem 57(9):3818-3834.
58. Liu ZD, et al. (2001) Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: Novel iron chelators with enhanced pFe3+ values. Bioorg Med Chem 9(3):563-573.
59. Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17:490-519.
60. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267(3):727-748.
61. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved proteinligand docking using GOLD. Proteins 52(4):609-623.
62. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245(1):43-53.